Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
Spondyloarthritis
•
Myositis
•
Psoriatic arthritis
•
General Rheumatology
•
Scleroderma
•
SLE
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Related Questions
How do you guide patients who seek online information about their disease to ensure it is accurate, supports their understanding, and minimizes unnecessary anxiety?
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
How do you approach treatment of a patient with active RA and a history of Lynch Syndrome?
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
How do you approach a patient with high titer ANA and a new diagnosis of ITP, but no other signs or symptoms suggestive of active rheumatologic disease?
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
